EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Heme arginate improves acute liver failure secondary to erythropoietic protoporphyria: a case report

Hua Ni, Beijin Chen, Aiping Huang, Tian Zhang, Hao Li, Shanhong Tang

Frontiers in Medicine · 23.04.2026 · 13

DOI: 10.3389/fmed.2026.1813183 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Medicine, online erschienen am 23.04.2026. Verfasst von Hua Ni und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Erythropoietic protoporphyria (EPP) is a rare inherited disorder with limited therapeutic options. For EPP patients with advanced cholestasis or liver failure, liver transplantation has long been regarded as the definitive therapy to address the hepatic crisis but does not offer a cure. Previous studies have reported that intravenous hemin/hematin may benefit some EPP patients, while the efficacy of intravenous heme arginate in treating EPP remains unreported. Case presentation We report a 24-year-old male with EPP and severe cholestasis. From 2017 to 2024, the patient was hospitalized eight times for recurrent episodes of jaundice and abdominal pain. These symptoms were effectively alleviated through a comprehensive treatment including artificial liver support (PE + DPMAS), hepatoprotective therapy, and high-glucose infusion. During his latest hospitalization in 2025, artificial liver support failed to improve the liver dysfunction, leading to progressive deterioration to liver failure. Notably, after two doses of intravenous heme arginate, the total bilirubin level gradually declined with significant improvement of ascites, coagulation dysfunction and neuropsychiatric symptoms. The patient was discharged with hepatoprotective therapy and light avoidance with no recurrence at 6-month follow-up.

Conclusion

This case suggests that intravenous heme arginate may provide clinical benefit in patients with EPP-associated liver failure and contributes to the limited literature supporting heme-based therapy in treating EPP hepatic crisis.

Schlagwörter

Stichwörter der Autor:innen

abdominal painartificial liver supporterythropoietic protoporphyriaheme arginatejaundiceliver failure

Autor:innen und Institutionen

  • Department of Gastroenterology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.
  • Department of Pathology, The General Hospital of Western Theater Command, Chengdu, Sichuan, China.
  • Department of Laboratory and Pathology, Lintong Rehabilitation and Convalescent Center, Xi'an, Shaanxi, China.

Zitieren

APA

Ni, H., Chen, B., Huang, A., Zhang, T., Li, H., & Tang, S. (2026). Heme arginate improves acute liver failure secondary to erythropoietic protoporphyria: a case report. Frontiers in Medicine, 13. https://doi.org/10.3389/fmed.2026.1813183

Vancouver

Ni H, Chen B, Huang A, Zhang T, Li H, Tang S. Heme arginate improves acute liver failure secondary to erythropoietic protoporphyria: a case report. Frontiers in Medicine. 2026;13. doi:10.3389/fmed.2026.1813183

BibTeX
@article{Ni2026,
  author = {Ni, Hua and Chen, Beijin and Huang, Aiping and Zhang, Tian and Li, Hao and Tang, Shanhong},
  title = {Heme arginate improves acute liver failure secondary to erythropoietic protoporphyria: a case report},
  journal = {Frontiers in Medicine},
  year = {2026},
  volume = {13},
  doi = {10.3389/fmed.2026.1813183}
}
Kostenlos starten →